Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Florida for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Florida only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Florida (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Aaron Flanders (NPI 1710182605)

Field	Value
Entity Type	Individual
Organization	Aaron Flanders
Address	1775 One Healing Pl
City	Tallahassee
State	FL
ZIP	32308
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	June 19, 2007

Payer Source	Total Paid
Medicare	$3.5M
Medicaid	$0

Key Findings

Practice profile and service mix: Billing is dominated by high-cost oncology infusions and biologics — the top revenue codes are J9271, J9173, and J9144 (pembrolizumab, durvalumab, and daratumumab), which together account for 54.8% of this provider's Medicare revenue. The broader code mix (including J0897 denosumab, J1439 ferric carboxymaltose, J1449 eflapegrastim, and multiple chemotherapy administration codes such as 96413, 96417, 96365, and 96367) indicates an infusion-centered hematology/oncology practice that delivers both immunotherapy/monoclonal antibody treatments and supportive care agents on-site.

Revenue concentration risk: The top three Medicare codes alone drive a majority share of revenue (precomputed at 54.8%), with individual contributions of J9271 = $645K (19.0%), J9173 = $613.8K (18.1%), and J9144 = $601.9K (17.7%). This concentration implies revenue sensitivity to utilization or pricing changes for a small set of oncology drugs.

Payer mix: The provider reports $3.5M in lifetime Medicare revenue and has no Medicaid billing on file (none), so operations are effectively single-payer at scale with almost all documented public-payer activity coming from Medicare. Analysts should treat Medicaid-market exposure as negligible for network or contracting decisions based on this file.

Competitive standing on key drugs: For several high-revenue molecules this provider ranks well above typical national peers — notably J9173 ranks #4 of 53 nationally (94th percentile; notably above typical national volume), and J9144 ranks #82 of 615 (86th percentile; typical, unremarkable volume). These positions suggest the provider is a major national participant for durvalumab and a high-volume user of daratumumab relative to most peers.

Extreme outlier signals in utilization: Multiple codes are flagged as extreme outliers in national comparisons, including J0897 (denosumab) at 99th percentile, J1439 (ferric carboxymaltose) at 99th percentile, and E/M and infusion codes such as 99214 and 96413 at or near the 99th percentile. Those extreme-outlier labels indicate utilization or billing volumes for those services are far above what is typical nationally and merit operational review if evaluating capacity, referral patterns, or supplier relationships.

Operational implications from administration codes: High-ranking chemotherapy administration and infusion add-on codes (96413 ranks #111 of 7514, 96417 ranks #51 of 3014, 96367 ranks #46 of 4032, and 96365 ranks #1039 of 8873) combined with large counts of drug-injection codes point to sustained throughput in an infusion suite rather than a primarily consultation-only practice. This mix implies needs for infusion nursing, drug procurement, and infusion chair capacity.

Clinical and outpatient demand: Office/outpatient E/M activity is also elevated — 99214 reports 1.3K claims and ranks #5132 of 479517 (99th percentile; extreme outlier) and 99215 and 99205 likewise rank notably above typical national volume — indicating consistent longitudinal outpatient management of complex oncology patients in addition to infusion encounters. High E/M volume supports an integrated clinic model with follow-up and care coordination responsibilities.

Tenure and market experience: The provider's NPI was enumerated 2007-06-19 (~19 years ago), indicating long-tenured practice presence in Tallahassee, FL. This tenure combined with the observed high-volume infusion and therapy mix suggests established referral relationships and operational experience in delivering oncology biologics and supportive therapies.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

89 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	15,000	$40	$645K
J9173	Injection, durvalumab, 10 mg	9,900	$60	$613.8K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	15,840	$40	$601.9K
J0897	Injection, denosumab, 1 mg	27,420	$20	$493.6K
J1439	Injection, ferric carboxymaltose, 1 mg	155,250	$1	$155.3K
Q5115	Injection, rituximab-abbs, biosimilar, (truxima), 10 mg	4,200	$30	$142.8K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,340	$90	$120.8K
J1449	Injection, eflapegrastim-xnst, 0.1 mg	4,500	$30	$112.5K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	920	$90	$85.4K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	32,070	$1	$64.1K

Showing 1–10 of 89

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 89 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Florida Distribution

Aaron Flanders — 11 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Florida

Full comparison — all codes billed, vs. state median

89 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	24	210	16,100	$40	$802.7K
Q5115	1	10	12,080	$30	$417.3K
J9144	2	80	9,000	$40	$410.6K
J9173	1	10	2,600	$60	$275.1K
J0897	4	1,060	3,290	$20	$106.5K
J1449	4	40	3,560	$30	$99.2K
J0881	1	50	9,000	$1	$32.4K
J1439	1	100	24,750	$1	$29.5K
96413	3	730	200	$100	$26.1K
93306	424	2,220	190	$100	$25.2K

Showing 1–10 of 89

Related Providers

Other providers that share a Tax Identification Number (TIN) with Aaron Flanders, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Riverside Radiology And Interventional Associates Inc	OH	Diagnostic Radiology Physician	$0	$30.3M
Somc Medical Care Foundation, Inc.	OH	Family Medicine Physician	$0	$25.3M
Musc Community Physicians	SC	Internal Medicine Physician	$0	$16.7M
Musc Community Physicians	SC	Family Medicine Physician	$0	$5.6M
Charles Butler	SC	Internal Medicine Physician	$3.8M	$0
Lindsay Gamble	SC	Family Nurse Practitioner	$3.7M	$0
Woodrow Coker	SC	Hospitalist Physician	$2.6M	$0
Scott Sommers	SC	Hematology & Oncology Physician	$2.3M	$0
Mohamed El Geneidy	SC	Hematology & Oncology Physician	$2.1M	$0
Anne Hutchison	SC	Hematology & Oncology Physician	$2M	$0

Nearby Providers

Other providers in the same ZIP code as Aaron Flanders, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Tallahassee Medical Center Inc	FL	General Acute Care Hospital	$0	$26.8M
Tallahassee Memorial Healthcare Inc	FL	General Acute Care Hospital	$0	$20.6M
Vitas Healthcare Corporation Of Florida	FL	Community Based Hospice Care Agency	$0	$18.6M
Dva Healthcare Renal Care, Inc.	FL	End-Stage Renal Disease (ESRD) Treatment Clinic/Center	$0	$11.6M
Big Bend Hospice, Inc.	FL	Community Based Hospice Care Agency	$0	$8.8M
Maxim Healthcare Services, Inc.	FL	Home Health Agency	$0	$8.7M
Harold Brooks	FL	Ophthalmology Physician	$3.2M	$0
Charles Newell	FL	Ophthalmology Physician	$2.5M	$0
Robert Steinmetz	FL	Ophthalmology Physician	$2.4M	$0
Nicholas Farber	FL	Ophthalmology Physician	$2M	$0

Aaron Flanders — Billing Profile & Reimbursement Data

Sign up for Aaron Flanders — Billing Profile & Reimbursement Data policy alerts

Aaron Flanders — Billing Profile & Reimbursement Data

Sign up for Aaron Flanders — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References